Form 8-K - Current report:
SEC Accession No. 0001193125-25-230925
Filing Date
2025-10-06
Accepted
2025-10-06 07:30:15
Documents
14
Period of Report
2025-10-05
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d55930d8k.htm   iXBRL 8-K 34676
2 EX-10.1 d55930dex101.htm EX-10.1 56713
3 EX-10.2 d55930dex102.htm EX-10.2 28649
  Complete submission text file 0001193125-25-230925.txt   260094

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA stok-20251005.xsd EX-101.SCH 2879
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE stok-20251005_lab.xml EX-101.LAB 17234
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE stok-20251005_pre.xml EX-101.PRE 10831
16 EXTRACTED XBRL INSTANCE DOCUMENT d55930d8k_htm.xml XML 3497
Mailing Address 45 WIGGINS AVENUE BEDFORD MA 01730
Business Address 45 WIGGINS AVENUE BEDFORD MA 01730 781-430-8200
Stoke Therapeutics, Inc. (Filer) CIK: 0001623526 (see all company filings)

EIN.: 471144582 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38938 | Film No.: 251375616
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)